Business Context and Reporting Period
This Form 8-K Current Report was filed by Sonoma Pharmaceuticals, Inc. (SNOA) on September 11, 2020, covering events occurring on September 8, 2020. The filing primarily addresses a change in senior management within the finance department.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It is a current report focused on corporate governance and personnel changes rather than financial performance.
Material Changes
- Appointment of CFO: The Board of Directors appointed Jerry Dvonch as Chief Financial Officer, effective September 8, 2020.
- Resignation of CFO: Grant Edwards resigned as Chief Financial Officer effective September 8, 2020.
- Compensation Details: Mr. Dvonch's annual salary is set at $200,000, with eligibility for a performance-based bonus up to 50% of his salary and standard equity grants. Mr. Edwards will assist with the transition at a rate of $200 per hour.
- Equity Vesting: Mr. Edwards' previously granted 2,609 shares of common stock are scheduled to vest on September 15, 2020. No further equity grants will be made to him.
Guidance, Outlook, and Risks
The filing contains standard forward-looking statements regarding the company's future activities and expectations. Management notes that actual results may differ materially due to risks and uncertainties discussed in the company's Annual Report on Form 10-K. No specific financial guidance or operational outlook was provided in this document.
Investor Verification Checklist
- Verify the effective date of the CFO transition and the start of the transition period for the outgoing CFO.
- Confirm the vesting schedule for the 2,609 shares of common stock granted to the departing CFO.
- Review the attached Exhibit 10.1 (Offer Letter) for specific performance goals tied to the new CFO's bonus structure.
- Check subsequent filings for any impact on the company's financial reporting timeline or internal controls due to the leadership change.